Search results
Showing 46 to 60 of 69 results for cystic fibrosis
NICE has developed a medtech innovation briefing (MIB) on the ThermoCool SmartTouch catheter for percutaneous radiofrequency ablation in atrial fibrillation
from guidance Mannitol dry powder for inhalation for treating cystic fibrosis Number TA266 Date issued November 2012 Other
This evidence summary has been updated and replaced by NICE guideline NG78.
Non-cystic fibrosis bronchiectasis: long-term azithromycin (ESUOM38)
This evidence summary has been updated and replaced by NICE guideline NG117.
Non-cystic fibrosis bronchiectasis: colistimethate sodium (ESUOM25)
This evidence summary has been updated and replaced by NICE guideline NG117.
Evidence-based recommendations on colistimethate sodium (Colobreathe) and tobramycin (TOBI Podhaler) dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis in people of 6 years and over.
Mannitol dry powder for inhalation for treating cystic fibrosis (TA266)
Evidence-based recommendations on mannitol dry powder for inhalation (Bronchitol) for treating cystic fibrosis (CF)
Living-donor lung transplantation for end-stage lung disease (IPG170)
Evidence-based recommendations on living-donor lung transplantation for end-stage lung disease. This involves removing a lung from each of the two donors and replacing the recipient's lungs with the donor lungs.
View recommendations for IPG170Show all sections
Sections for IPG170
Discontinued [GID-TA10310]
Eteplirsen for treating Duchenne muscular dystrophy [ID1003]
Discontinued [GID-HST10007]
Ataluren for treating cystic fibrosis in people with a CFTR gene nonsense mutation [ID955]
Discontinued [GID-TA11262]
Awaiting development [GID-TA11430] Expected publication date: TBC